Castro Villegas MDC, Escudero Contreras A, Miranda García MD, Collantes Estévez E. [How to optimize the antiTNF alpha therapy in spondylitis?].
REUMATOLOGIA CLINICA 2012;
8 Suppl 1:S26-S31. [PMID:
22418285 DOI:
10.1016/j.reuma.2012.01.002]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Revised: 12/31/2011] [Accepted: 01/18/2012] [Indexed: 05/31/2023]
Abstract
TNFalpha inhibitors have been a major advance in the treatment of spondyloarthropathies, having demonstrated their safety and efficacy, with higher response and survival rates than those observed in patients with rheumatoid arthritis. The fact that disease modifying anti-arthritic drugs (DMARD) have shown utility in the treatment of this disease, especially in the axial forms, gives them greater importance, since it is known that up to 30%of patients do not respond to treatment with non-steroidal anti-inflammatory drugs. However, we must take into account that these drugs are expensive and not without side effects, so it is necessary to optimize their use. We intend to review the use of antiTNF alpha in spondyloarthropathies and review the available evidence on strategies that can help with their rational use.
Collapse